Considering the crucial role played by IL-17, produced by both Th17 and γδT17 cells in the pathogenesis of psoriasis, recent therapeutic strategies have primarily focused on reducing IL-17 production, counteracting its effects by corresponding inhibitors or antibodies, or limit the chemotaxis of Th17 and γδT17 cells.429,441–448 However, adverse side effects such as neurological diseases, infections, and liver dysfunction have been reported.449–451 This may be partly attributed to the significant role IL-17 plays in combating certain pathogens, particularly fungal infections. Here, IL17A is linked to fungal infectious disease.